Percutaneous glycerol rhizolysis of the trigeminal ganglion for the treatment of idiopathic and classic trigeminal neuralgia: Outcomes and complications
European Journal of Neurology · 2023
DOI: 10.1111/ene.15977 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Raviteja Bethamcharla und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Columbia University Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Trigeminal Neuralgia, Radiosurgery. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background and purpose Patients with idiopathic trigeminal neuralgia (TN) with absent arterial contact or venous contact only and classic TN with morphological changes of the trigeminal nerve secondary to venous compression are not routinely recommended microvascular decompression at our institution. In patients with these anatomical subtypes of TN, limited data exists describing the outcomes of percutaneous glycerol rhizolysis (PGR) of the trigeminal ganglion (TG).
Methods
We performed a retrospective single‐center cohort study and analyzed outcomes and complications after PGR of the TG. Clinical outcome after PGR of the TG was assessed via the Barrow Neurological Institute (BNI) Pain Scale.
Results
Forty‐five patients underwent a total of 66 PGRs of the TG. At short‐term follow‐up, 58 procedures (87.9%) resulted in a BNI score of I (i.e., freedom from pain without medication). At a median follow‐up of 3.07 years, 18 procedures (27.3%) resulted in a BNI score of I, 12 procedures (18.1%) resulted in BNI score of IIIa, and 36 procedures (54.5%) resulted in a BNI score of IIIb‐V. The median length of freedom from pain without medication was 1.5 years. Eighteen procedures (27.3%) caused hypesthesia and two (3.0%) caused paresthesias. There were no serious complications.
Conclusion
In patients with these anatomical subtypes of TN there was a high rate of short‐term pain relief for the first 1–2 years and thereafter a large proportion of patients experienced pain relapse. In this patient group, PGR of the TG represents a safe procedure that is efficacious in the short term.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, Columbia University Medical Center, New York, New York, USA.
- Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Danish Headache Centre, Department of Neurology, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark.
- Department of Neurological Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
ORCID-Profile: Raviteja Bethamcharla
Zitieren
APA
Bethamcharla, R., Abou-Al-Shaar, H., Maarbjerg, S., Chang, Y. F., Gacka, C. N., & Sekula, R. F. (2023). Percutaneous glycerol rhizolysis of the trigeminal ganglion for the treatment of idiopathic and classic trigeminal neuralgia: Outcomes and complications. European Journal of Neurology. https://doi.org/10.1111/ene.15977
Vancouver
Bethamcharla R, Abou-Al-Shaar H, Maarbjerg S, Chang YF, Gacka CN, Sekula RF. Percutaneous glycerol rhizolysis of the trigeminal ganglion for the treatment of idiopathic and classic trigeminal neuralgia: Outcomes and complications. European Journal of Neurology. 2023. doi:10.1111/ene.15977
BibTeX
@article{Bethamcharla2023,
author = {Bethamcharla, Raviteja and Abou-Al-Shaar, Hussam and Maarbjerg, Stine and Chang, Yue-Fang and Gacka, Caroline N and Sekula, Raymond F},
title = {Percutaneous glycerol rhizolysis of the trigeminal ganglion for the treatment of idiopathic and classic trigeminal neuralgia: Outcomes and complications},
journal = {European Journal of Neurology},
year = {2023},
doi = {10.1111/ene.15977}
}
EUVIMED